TMEM276-ZFTRAF1 readthrough fusion protein (TMEM276-ZFTRAF1)

The TMEM276-ZFTRAF1 gene locus is a product of read-through transcription between TMEM276 (LOC84773) and the CYHR1 (cysteine and histidine rich 1) genes, generating a fusion protein that contains sequence domains from both parent genes[2]. The molecular function of the resulting protein is not well defined; functional inference suggests possible involvement in zinc ion binding and cellular processes such as mRNA processing and autophagy which are known functions for ZFTRAF1, but direct evidence for the fusion protein itself is lacking[1][2][3]. Variants in the ZFTRAF1 component have been associated with severe neurodevelopmental disorders, particularly those displaying microcephaly and hypotonia, but no clinical or pharmacological data specifically implicate the read-through TMEM276-ZFTRAF1 protein as a therapeutic target, biomarker, or drug-interacting molecule at present[1][2][3]. There is no recognized role for this fusion protein in drug response, disease pathogenesis (other than overlap with ZFTRAF1-centric disease), or as an actionable receptor or enzyme. The protein remains **uncharacterized** in terms of biological pathways and disease relevance, with no associated drugs, clinical biomarkers, or safety concerns documented in the literature or protein databases[2][7].

Other names

LOC84773-CYHR1Uncharacterized protein LOC157542LOC84773-CYHR1 readthroughTMEM276-CYHR1 readthroughTMEM276-ZFTRAF1

None reported; there are no drugs known to act on this fusion protein